Antipsychotic drugs for anorexia nervosa

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 6, 2016, Pages

  Claudino, Angélica M ^a   Hay, Phillipa J ^b   Silva de Lima, Mauricio ^c   Schmidt, Ulrike H ^d   Treasure, Janet ^e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c GENENTECH INC   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Department of Academic Psychiatry ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ANOREXIA NERVOSA; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SYSTEMATIC REVIEW;

EID: 84971624420     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006816.pub2     Document Type: Review

References (59)

1. Aalto-Setala T, Martunnen M, Tuulio-Henriksson A, Poilolainen K, Lonnqvist J. One-month prevalence of depression and other DSM-IV disorders among young adults. Psychological Medicine 2001;31:791-801.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
3. American Psychiatric Association. Practice Guidelines for the Treatment of Psychiatric Disorders. Arlington, VA: American Psychiatric Association, 2006.
4. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, et al. An open trial of olanzapine in anorexia nervosa. Journal of Clinical Psychiatry 2004;65(11):1480-2.
5. Bianco G, Claps M, Marinucci S, Montecchi F. Use of risperidone in adolescent anorexia nervosa. Italian Journal of Psychiatry and Behavioural Sciences 2000;10:50-2.
6. Bosanac P, Norman T, Burrows G, Beumont P. Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?. Australian and New Zealand Journal of Psychiatry 2005;39:146-53.
7. Claudino A, Hay P, Lima MS, Bacaltchuk J, Schmidt U, Treasure J. Antidepressants for anorexia nervosa. Cochrane Database of Systematic Reviews 2006, Issue 1.
8. Connan F, Stanley S. Biology of appetite and weight regulation. In: Treasure J, Schmidt U, van FurthE editor(s). Handbook of Eating Disorders. 2nd Edition. Chichester: John Wiley and Sons, 2003:63-87.
9. Cooper Z, Cooper PJ, Fairburn CG. The validity of the eating disorder examination and its subscales. British Journal of Psychiatry 1989;154:807-12.
10. Dally P, Sargant W. A new treatment of anorexia nervosa. British Medical Journal 1960;1:1770-3.
11. Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966;2:793-5.
12. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. BMJ Publication Group, 2001.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
14. Eisler I, Dare C, Russell GF, Szmukler G, Le-Grange D, Dodge E. Family and individual therapy in anorexia nervosa. A 5-year follow-up. Archives of General Psychiatry 1997;54:1025-30.
15. Eisler I, Dare C, Hodes M, Russell G, Dodge E, Le Grange D. Family therapy for adolescent anorexia nervosa: the results of a controlled comparison of two family interventions. Journal of Child Psychology and Psychiatry 2000;41(6):727-36.
16. Fairburn CG, Cooper Z, Doll HA, Welch SL. Risk factors for anorexia nervosa: three integrated case-control comparisons. Archives of General Psychiatry 1999;56:468-76.
17. Fairburn CG, Harrison PJ. Eating Disorders. Lancet 2003;361:407-16.
18. Favaro A, Ferrara S, Santonastaso P. The spectrum of eating disorders in young women: a prevalence study in a general population sample. Psychosomatic Medicine 2004;65:701-8.
19. Frank GK, Kaye WH, Meltzer CC, Price JC, Greer P, McConaha C, et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biological Psychiatry 2002;52(9):896-906.
20. Frank GK, Bailer UF, Henry SE, Drevets W, Meltzer CC, Price JC, et al. Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]raclopride. Biological Psychiatry 2005;58(11):908-12.
21. Garner DM, Olmsted MP, Polivy J. Develpment and validation of a multidimensional Eating Disorder Inventory for anorexia and bulimia. International Journal of Eating Disorders 1983;2:15-34.
22. Gaskill J, Treat T, McCabe E, Marcus M. Does olanzapine affect the rate of weight gain among inpatients with eating disorders?. Eating Disorders Review 2001;12:1-2.
23. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive-Compulsive Scale (YBOCS): Part II. Validity. Archives of General Psychiatry 1989;46:1012-6.
24. Halmi KA, Agras WS, Crow S, Mitchell J, Wilson GT, Bryson SW, et al. Predictors of treatment acceptance and completion in anorexia nervosa: implications for future study designs. Archives of General Psychiatry 2005;62(7):76-81.
25. Hay P, Bacaltchuk J, Claudino A, Ben-Tovim D, Young PY. Individual psychotherapy in the outpatient treatment of adults with anorexia nervosa. Cochrane Database of Systematic Reviews 2003, Issue 4.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
27. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Vol. issue 4, Chichester, UK: John Wiley & Sons, Ltd, 2006.
28. Hoek HW, van Hoeken D. Review of the prevalence and incidence of eating disorders. International Journal of Eating Disorders 2003;34:383-96.
29. Hudson JI, Hiripi E, Pope Jr HG, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry 2006; Vol. in press.
30. Jacobi C, Hayward C, de Zwaan M, Kraemer HC, Agras WS. Coming to terms with risk factors for eating disorders: application of risk terminology and suggestions for a general taxonomy. Psychological Bulletin 2004;130(1):19-65.
31. Kay SR, Opler LA, Lindenmayer JP. Reliability and Validity of the positive and negative syndrome scale for schizophrenia. Psychiatry Research 1988;23:99-110.
32. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration: Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior?. Archives of General Psychiatry 1991;48(6):556-62.
33. Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 1999;21(4):503-6.
34. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biological Psychiatry 2001;49(7):644-52.
35. Lindblat F, Lindberg L, Hjern A. Improved survival in adolescent patients with anorexia nervosa: a comparison of two Swedish national cohorts of female inpatients. American Journal of Psychiatry 2006;163(8):1433-5.
36. Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, et al. Olanzapine treatment of anorexia nervosa: a retrospective study. International Journal of Eating Disorders 2003;33(2):234-7.
37. Mondraty N, Laird Birmingham C, Touyz S, Sundakov V, Chapman L, Beaumont P. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australasian Psychiatry 2005;13(1):72-5.
38. Montecchi F, Magnani M, Marinucci S, Gambara M, Diamanti A. Risperidone in the control of negative symptoms in anorexia nervosa in adolescents. Minerva Psichiatrica 1998;39:205-9.
39. Morgan, HG, Russell, GF . Value of family background and clinical features as predictors of longterm outcome in anorexia nervosa: Four year follow-up study of 41 patients. Psychological Medicine 1975;5:355-71.
40. Morgan HG, Hayward AE. Clinical assessment of anorexia nervosa. The Morgan-Russell assessment schedule. British Journal of Psychiatry 1988;152:367-71.
41. National Collaborating Centre for Mental Health. Eating disorders: core interventions in the treatment and management fo anorexia nervosa, bulimia nervosa and related eating disorders. London: British Psychological Society and Royal College of Psychiatrists, 2004.
42. Nielsen S. Epidemiology and mortality of eating disorders. Psychiatric Clinics of North America 2001;24(2):201-14.
43. Powers PS, Santana CA, Bannen YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. International Journal of Eating Disorders 2002;32:146-54.
44. Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa. Expert Opinion in Pharmacotherapy 2004;5(11):2287-92.
45. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Anorexia Nervosa. Australian and New Zealand clinical practice guidelines for the treatment of Anorexia Nervosa. Australian and New Zealand Journal of Psychiatry 2004;38:659-70.
46. The Nortic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 4.2 for Windows. Copenhagen: The Nortic Cochrane Centre, The Cochrane Collaboration, 2003.
47. Ruggiero GM, Laini V, Mauri MC, Ferrari VM, Clemente A, Lugo F, et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001;25(5):1049-59.
48. Russell GFM. Anorexia nervosa: its identity as an illness and its treatment. Modern Trends in Psychological Medicine. London: Butterworth, 1970:131-64.
49. Russell GF, Szmukler GI, Dare C, Eisler I. An evaluation of family therapy in anorexia and bulimia nervosa. Archives of General Psychiatry 1987;44:1047-56.
50. Schmidt U. Aetiology of eating disorders in the 21st century. New answers to old questions. European Child and Adolescent Psychiatry 2003;12 Suppl 1:30-7.
51. Steinhausen HC. The outcome of anorexia nervosa in the 20th century. American Journal of Psychiatry 2002;159:1284-93.
52. Sullivan PF. Mortality in anorexia nervosa. American Journal of Psychiatry 1995;152:1073-4.
53. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatrica Scandinavica 2000;101:416-32.
54. Treasure J, Schmidt U. Anorexia Nervosa. Clinical Evidence. Vol. 14, BMJ Publishing Group, 2005:1-3.
55. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatrica Scandinavica 1982;66:445-50.
56. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa, a double-blind placebo-controlled trial with sulpiride.. British Journal of Psychiatry 1984;144:288-92.
57. Walsh T. Fluoxetine after weight restoration in anorexia nervosa. JAMA 2006;295(22):2605-12.
58. Weizman A, Tyano S, Wijsenbeek H, Ben David M. Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychotherapy and Psychosomatics 1985;43(3):136-40..
59. World Health Organization. The ICD-10 Classification of Mental and Behavior Disorders. 10th Edition. Geneva: World Health Organization, 1992.